vs
CIVITAS RESOURCES, INC.（CIVI）与登士柏西诺德（XRAY）财务数据对比。点击上方公司名可切换其他公司
CIVITAS RESOURCES, INC.的季度营收约是登士柏西诺德的1.2倍（$1.2B vs $961.0M），登士柏西诺德同比增速更快（6.2% vs -8.2%），过去两年CIVITAS RESOURCES, INC.的营收复合增速更高（1.8% vs 0.4%）
Civitas Resources是一家总部位于美国的可持续能源企业，主要从事石油、天然气及天然气凝液的勘探、开发与生产业务，核心运营区域位于科罗拉多州丹佛-朱尔斯堡盆地，专注于低排放的负责任能源开发，服务北美能源市场需求。
登士柏西诺德是美国牙科设备及耗材制造商，业务覆盖全球120多个国家，在21个国家设有生产工厂。该公司前身为1993年Gendex公司以5.9亿美元收购登士柏国际后整合组建的企业，是全球牙科领域的重要供应商。
CIVI vs XRAY — 直观对比
营收规模更大
CIVI
是对方的1.2倍
$961.0M
营收增速更快
XRAY
高出14.4%
-8.2%
两年增速更快
CIVI
近两年复合增速
0.4%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $961.0M |
| 净利润 | — | $-146.0M |
| 毛利率 | — | 46.1% |
| 营业利润率 | 20.0% | -14.5% |
| 净利率 | — | -15.2% |
| 营收同比 | -8.2% | 6.2% |
| 净利润同比 | — | 66.0% |
| 每股收益（稀释后） | $1.99 | $-0.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CIVIXRAY
| Q4 25 | — | $961.0M | ||
| Q3 25 | $1.2B | $904.0M | ||
| Q2 25 | $1.1B | $936.0M | ||
| Q1 25 | $1.2B | $879.0M | ||
| Q4 24 | $1.3B | $905.0M | ||
| Q3 24 | $1.3B | $951.0M | ||
| Q2 24 | $1.3B | $984.0M | ||
| Q1 24 | $1.3B | $953.0M |
净利润CIVIXRAY
| Q4 25 | — | $-146.0M | ||
| Q3 25 | — | $-427.0M | ||
| Q2 25 | — | $-45.0M | ||
| Q1 25 | — | $20.0M | ||
| Q4 24 | — | $-430.0M | ||
| Q3 24 | — | $-494.0M | ||
| Q2 24 | — | $-4.0M | ||
| Q1 24 | — | $18.0M |
毛利率CIVIXRAY
| Q4 25 | — | 46.1% | ||
| Q3 25 | — | 48.8% | ||
| Q2 25 | — | 52.4% | ||
| Q1 25 | — | 53.0% | ||
| Q4 24 | — | 49.3% | ||
| Q3 24 | — | 52.1% | ||
| Q2 24 | — | 51.9% | ||
| Q1 24 | — | 53.1% |
营业利润率CIVIXRAY
| Q4 25 | — | -14.5% | ||
| Q3 25 | 20.0% | -24.1% | ||
| Q2 25 | 15.3% | -13.7% | ||
| Q1 25 | 20.7% | 7.2% | ||
| Q4 24 | 15.4% | -56.2% | ||
| Q3 24 | 30.6% | -48.6% | ||
| Q2 24 | 21.6% | 5.1% | ||
| Q1 24 | 15.9% | 4.4% |
净利率CIVIXRAY
| Q4 25 | — | -15.2% | ||
| Q3 25 | — | -47.2% | ||
| Q2 25 | — | -4.8% | ||
| Q1 25 | — | 2.3% | ||
| Q4 24 | — | -47.5% | ||
| Q3 24 | — | -51.9% | ||
| Q2 24 | — | -0.4% | ||
| Q1 24 | — | 1.9% |
每股收益（稀释后）CIVIXRAY
| Q4 25 | — | $-0.74 | ||
| Q3 25 | $1.99 | $-2.14 | ||
| Q2 25 | $1.34 | $-0.22 | ||
| Q1 25 | $1.99 | $0.10 | ||
| Q4 24 | $1.56 | $-2.09 | ||
| Q3 24 | $3.01 | $-2.46 | ||
| Q2 24 | $2.15 | $-0.02 | ||
| Q1 24 | $1.74 | $0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $56.0M | $326.0M |
| 总债务越低越好 | $5.1B | $2.3B |
| 股东权益账面价值 | $6.7B | $1.3B |
| 总资产 | $15.1B | $5.4B |
| 负债/权益比越低杠杆越低 | 0.77× | 1.70× |
8季度趋势，按日历期对齐
现金及短期投资CIVIXRAY
| Q4 25 | — | $326.0M | ||
| Q3 25 | $56.0M | $363.0M | ||
| Q2 25 | $69.0M | $359.0M | ||
| Q1 25 | $20.0M | $398.0M | ||
| Q4 24 | $76.0M | $272.0M | ||
| Q3 24 | $47.1M | $296.0M | ||
| Q2 24 | $91.9M | $279.0M | ||
| Q1 24 | $52.1M | $291.0M |
总债务CIVIXRAY
| Q4 25 | — | $2.3B | ||
| Q3 25 | $5.1B | — | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $5.1B | — | ||
| Q4 24 | $4.5B | $1.7B | ||
| Q3 24 | $4.8B | — | ||
| Q2 24 | $4.9B | — | ||
| Q1 24 | $4.4B | — |
股东权益CIVIXRAY
| Q4 25 | — | $1.3B | ||
| Q3 25 | $6.7B | $1.5B | ||
| Q2 25 | $6.8B | $2.0B | ||
| Q1 25 | $6.7B | $2.0B | ||
| Q4 24 | $6.6B | $1.9B | ||
| Q3 24 | $6.7B | $2.5B | ||
| Q2 24 | $6.6B | $3.1B | ||
| Q1 24 | $6.6B | $3.3B |
总资产CIVIXRAY
| Q4 25 | — | $5.4B | ||
| Q3 25 | $15.1B | $5.7B | ||
| Q2 25 | $15.4B | $6.1B | ||
| Q1 25 | $15.3B | $6.0B | ||
| Q4 24 | $14.9B | $5.8B | ||
| Q3 24 | $15.0B | $6.6B | ||
| Q2 24 | $15.0B | $6.9B | ||
| Q1 24 | $15.1B | $7.1B |
负债/权益比CIVIXRAY
| Q4 25 | — | 1.70× | ||
| Q3 25 | 0.77× | — | ||
| Q2 25 | 0.79× | — | ||
| Q1 25 | 0.76× | — | ||
| Q4 24 | 0.68× | 0.90× | ||
| Q3 24 | 0.73× | — | ||
| Q2 24 | 0.74× | — | ||
| Q1 24 | 0.67× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $860.0M | $101.0M |
| 自由现金流经营现金流 - 资本支出 | — | $60.0M |
| 自由现金流率自由现金流/营收 | — | 6.2% |
| 资本支出强度资本支出/营收 | — | 4.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $104.0M |
8季度趋势，按日历期对齐
经营现金流CIVIXRAY
| Q4 25 | — | $101.0M | ||
| Q3 25 | $860.0M | $79.0M | ||
| Q2 25 | $298.0M | $48.0M | ||
| Q1 25 | $719.0M | $7.0M | ||
| Q4 24 | $858.2M | $87.0M | ||
| Q3 24 | $835.0M | $141.0M | ||
| Q2 24 | $359.0M | $208.0M | ||
| Q1 24 | $813.0M | $25.0M |
自由现金流CIVIXRAY
| Q4 25 | — | $60.0M | ||
| Q3 25 | — | $40.0M | ||
| Q2 25 | — | $16.0M | ||
| Q1 25 | — | $-12.0M | ||
| Q4 24 | — | $36.0M | ||
| Q3 24 | — | $98.0M | ||
| Q2 24 | — | $156.0M | ||
| Q1 24 | — | $-9.0M |
自由现金流率CIVIXRAY
| Q4 25 | — | 6.2% | ||
| Q3 25 | — | 4.4% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | -1.4% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 10.3% | ||
| Q2 24 | — | 15.9% | ||
| Q1 24 | — | -0.9% |
资本支出强度CIVIXRAY
| Q4 25 | — | 4.3% | ||
| Q3 25 | — | 4.3% | ||
| Q2 25 | — | 3.4% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 5.6% | ||
| Q3 24 | — | 4.5% | ||
| Q2 24 | — | 5.3% | ||
| Q1 24 | — | 3.6% |
现金转化率CIVIXRAY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.35× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.39× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CIVI
| Crude Oil Natural Gas And Natural Gas Liquids | $1.2B | 99% |
| Oil And Gas Operation And Maintenance | $8.0M | 1% |
| Natural Gas Reserves | $2.0M | 0% |
XRAY
| Essential Dental Solutions | $372.0M | 39% |
| Equipment And Instruments | $160.0M | 17% |
| Implants And Prosthetics | $150.0M | 16% |
| CADCAM | $139.0M | 14% |
| Wellspect Healthcare | $88.0M | 9% |
| Orthodontics | $52.0M | 5% |
